Rchr
J-GLOBAL ID：200901075469923957   Update date: Sep. 27, 2024

Toyama Tatsuya

トオヤマ タツヤ | Toyama Tatsuya
Affiliation and department：
Nagoya City University Graduate School of Medical Sciences Department of Breast Surgery

About Nagoya City University Graduate School of Medical Sciences Department of Breast Surgery


Job title： Professor
Homepage URL  (1)： http://www.med.nagoya-cu.ac.jp/mammal.dir/index.html
Research field  (1)： General surgery, pediatric surgery
Research keywords  (1)： 乳癌
Research theme for competitive and other funds  (31)：
  • 2024 - 2027 転写共役因子を標的としたホルモン療法抵抗性乳癌に対する新規治療法の開発
  • 2024 - 2027 SYNJ2遺伝子を標的としたホルモン療法抵抗性乳がんに対する革新的治療法の開発
  • 2023 - 2027 Innovative smartphone psychotherapy targeting both fear of recurrence and persistent chronic pain after curative cancer resection
  • 2022 - 2027 致死性疾患の術後遷延痛と再発不安に対する「オンライン集団ACTプログラム」の開発
  • 2023 - 2026 Novel treatment strategy for breast cancer using memory T cells
Show all
Papers (297)：
  • Yutaka Yamamoto, Chikako Yamauchi, Tatsuya Toyama, Shigenori Nagai, Takehiko Sakai, Goro Kutomi, Michio Yoshimura, Masaaki Kawai, Shoichiro Ohtani, Kazunori Kubota, et al. Correction: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment. Breast cancer (Tokyo, Japan). 2024
  • Yutaka Yamamoto, Chikako Yamauchi, Tatsuya Toyama, Shigenori Nagai, Takehiko Sakai, Goro Kutomi, Michio Yoshimura, Masaaki Kawai, Shoichiro Ohtani, Kazunori Kubota, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment. Breast cancer (Tokyo, Japan). 2024. 31. 3. 340-346
  • Maho Kusudo, Mitsuo Terada, Nari Kureyama, Yumi Wanifuchi-Endo, Takashi Fujita, Tomoko Asano, Akiko Kato, Makiko Mori, Nanae Horisawa, Tatsuya Toyama. Characterizing user demographics in posts related to breast, lung and colon cancer on Japanese twitter (X). Scientific reports. 2024. 14. 1. 6485-6485
  • Tatsuo Akechi, Toshiaki A Furukawa, Hisashi Noma, Hiroji Iwata, Tatsuya Toyama, Kenji Higaki, Hiromichi Matsuoka, Sadamoto Zenda, Tsuguo Iwatani, Kazuhisa Akahane, et al. Optimizing smartphone psychotherapy for depressive symptoms in patients with cancer: Multiphase optimization strategy using a decentralized multicenter randomized clinical trial (J-SUPPORT 2001 Study). Psychiatry and clinical neurosciences. 2024
  • Masaya Hattori, Naoko Honma, Shigenori Nagai, Kazutaka Narui, Tomoko Shigechi, Yukinori Ozaki, Masayuki Yoshida, Takashi Sakatani, Eiichi Sasaki, Yuko Tanabe, et al. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines. Breast cancer (Tokyo, Japan). 2024
ｍore...
MISC (87)：
ｍore...
Lectures and oral presentations  (403)：
  • Single-Agent Activity of U3-1402, a HER3-Targeting Antibody-Drug Conjugate, in Breast Cancer Patients: Phase 1 Dose Escalation Study.
    (The 53th Annual meeting of American Society of Clinical Oncology (ASCO) 2018)
  • TransNEOS: Validation of the Oncotype DX Recurrence Score testing core needle biopsy samples from NEOS as predictor of clinical response to neoadjuvant endocrine therapy for postmenopausal ER+, HER2-negative breast cancer patients.
    (2017 Annual San Antonio Breast Cancer Symposium (San Antonio, U.S.A) 2017)
  • NEOS: A randomized, open label, phase 3 trial of adjuvant chemotherapy for postmenopausal breast cancer patients who responded to neoadjuvant letrozole: First report of long-term outcome and prognostic value of response to neoadjuvant endocrine therapy.
    (2017 Annual San Antonio Breast Cancer Symposium (San Antonio, U.S.A) 2017)
  • The prognostic impact of Retinoic Acid-Induced 2(RAI2) expression in ERα-positive breast cancer patients.
    (2017 Annual San Antonio Breast Cancer Symposium (San Antonio, U.S.A) 2017)
  • Everolimus (EVE) + letrozole (LET) in patients (pts) with estrogen receptor_positive (ER+), human epidermal growth factor receptor 2_negative (HER2-) advanced breast cancer (ABC): subgroup analysis of first line (1L) progression-free survival (PFS) by rac
    (ESMO (European Society for Medical Oncology)-Asia2017 Congress, 2017)
ｍore...
Education (1)：
  • 1983 - 1989 Nagoya City University Faculty of Medicine
Professional career (1)：
  • 医学博士 (名古屋市立大学医学部)
Work history (8)：
  • 2016/06 - 現在 Nagoya City University Graduate School of Medical Sciences Department of Breast Surgery Professor
  • 2012/10 - 2016/05 Nagoya City University Graduate School of Medical Sciences, Department of Oncology, Immunology and Surgery
  • 2009/10 - 2012/09 Nagoya City University Graduate School of Medical Sciences, Department of Oncology, Immunology and Surgery
  • 2007/04 - 2009/09 Nagoya City University Graduate School of Medical Sciences, Department of Oncology, Immunology and Surgery
  • 2005/10 - 2007/03 Nagoya City University Graduate School of Medical Sciences, Department of Oncology, Immunology and Surgery
Show all
Committee career (6)：
  • 2018 - 現在 日本癌治療学会 教育委員
  • 2016 - 現在 日本乳癌学会 診療ガイドライン委員会 委員
  • 2016 - 現在 日本乳癌学会 乳癌診療ガイドライン・薬物療法小委員会 委員長
  • 2018 - 2020 日本乳癌学会 地方創生委員会 [中部地区]事務局長
  • 2015 - 2020 日本乳癌学会 試験問題作成委員会 副委員長
Show all
Awards (2)：
  • 2007 - 第45回日本癌治療学会総会優秀演題賞
  • 2000 - 第6回日本乳癌学会研究奨励賞
Association Membership(s) (5)：
日本臨床腫瘍学会 ,  日本癌治療学会 ,  日本外科学会 ,  日本乳癌学会 ,  日本癌学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM